| Literature DB >> 32894746 |
David Moloney1,2, John O'Connor1, Louise Newman1, Siobhan Scarlett1, Belinda Hernandez1, Rose Anne Kenny1,2, Roman Romero-Ortuno1,2.
Abstract
BACKGROUND: Orthostatic hypotension (OH) can be assessed with non-invasive continuous beat-to-beat haemodynamic monitoring during active stand (AS) testing; this yields large volumes of data outside the scope of the traditional OH definition. We explored clinical associations of different AS patterns in participants from Wave 1 of the Irish Longitudinal Study on Ageing.Entities:
Keywords: active stand; falls; older people; orthostatic hypotension; orthostatic intolerance; physiologic monitoring
Mesh:
Year: 2021 PMID: 32894746 PMCID: PMC8098799 DOI: 10.1093/ageing/afaa174
Source DB: PubMed Journal: Age Ageing ISSN: 0002-0729 Impact factor: 10.668
Figure 1Hypothesised eight mutually exclusive groups based on three sequential SBP features during the AS. The column on the right shows the classification result (in brackets: number of participants in the group, percentage of the total sample).
Figure 2Graphical visualisation of the eight AS groups.
Characterisation of the overall sample and the eight AS groups
| Overall | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | Group 7 | Group 8 |
| |
|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) | 4,899 (100.0) | 272 (5.6) | 43 (0.9) | 209 (4.3) | 632 (12.9) | 145 (3.0) | 38 (0.8) | 248 (5.1) | 3,312 (67.6) | |
| Mean age in years (SD) | 61.0 (8.8) | 64.5 (9.3) | 68.1 (10.5) | 60.3 (7.7) | 61.6 (8.6) | 66.9 (9.2) | 68.8 (9.5) | 61.3 (9.2) | 60.2 (8.5) | <0.001* |
| Female gender, | 2,703 (55.2) | 172 (63.2) | 23 (53.5) | 142 (67.9) | 364 (57.6) | 101 (69.7) | 18 (47.4) | 153 (61.7) | 1730 (52.2) | <0.001# |
| Non-frail, | 3,471 (72.6) | 174 (65.4) | 31 (75.6) | 155 (74.9) | 448 (72.4) | 80 (57.6) | 24 (64.9) | 156 (65.3) | 2,403 (74.3) | <0.001# |
| Pre-frail or frail, | 1,313 (27.5) | 92 (34.6) | 10 (24.4) | 52 (25.1) | 171 (27.6) | 59 (42.5) | 13 (35.1) | 83 (34.7) | 833 (25.7) | <0.001# |
| Mean time to stand in seconds (SD) | 7.6 (3.0) | 7.9 (2.7) | 8.3 (3.5) | 7.3 (2.3) | 7.5 (2.8) | 9.7 (4.5) | 9 (3.8) | 8.1 (3.2) | 7.5 (2.9) | <0.001* |
| Median MMSE (IQR) | 29 (2) | 29 (2) | 28 (3) | 29 (2) | 29 (2) | 29 (2) | 29 (3) | 29 (2) | 29 (2) | <0.001* |
| Multimorbidity, | 2,236 (45.6) | 132 (48.5) | 22 (51.2) | 85 (40.7) | 303 (47.9) | 92 (63.5) | 27 (71.1) | 113 (45.6) | 1,462 (44.1) | <0.001# |
| Atrial fibrillation, | 109 (2.3) | 7 (2.6) | 2 (4.7) | 2 (1.0) | 16 (2.6) | 3 (2.1) | 4 (10.5) | 3 (1.2) | 72 (2.2) | 0.024# |
| Parkinson’s disease, | 15 (0.3) | 2 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (2.1) | 0 (0.0) | 3 (1.2) | 7 (0.2) | <0.001# |
| Diabetes mellitus, | 300 (6.1) | 17 (6.3) | 5 (11.6) | 7 (3.4) | 35 (5.5) | 15 (10.3) | 5 (13.2) | 14 (5.7) | 202 (6.1) | 0.065# |
| Hypertension, | 1934 (39.7) | 119 (44.1) | 24 (57.1) | 98 (47.1) | 294 (46.9) | 63 (43.8) | 16 (42.1) | 108 (43.9) | 1,212 (36.7) | 0.001# |
| Polypharmacy, | 830 (17.0) | 68 (25.1) | 13 (30.2) | 25 (12.0) | 98 (15.6) | 46 (32.4) | 9 (24.3) | 55 (22.4) | 516 (15.6) | <0.001# |
| Anti-hypertensive medications, | ||||||||||
| Overall | 1,553 (31.7) | 99 (36.4) | 16 (37.2) | 60 (28.7) | 211 (33.4) | 67 (46.2) | 19 (50.0) | 77 (31.1) | 1,004 (30.3) | <0.001# |
| Beta blockers | 563 (11.5) | 55 (20.3) | 7 (16.3) | 28 (13.5) | 81 (12.9) | 27 (19.0) | 3 (8.1) | 26 (10.6) | 336 (10.2) | <0.001# |
| Diuretics | 289 (5.9) | 17 (6.3) | 5 (11.6) | 7 (3.4) | 35 (5.0) | 13 (9.2) | 4 (10.8) | 16 (6.5) | 192 (5.8) | 0.211# |
| Angiotensin-Converting Enzyme (ACE) inhibitors/Angiotensin receptor blockers | 1,047 (21.5) | 53 (19.6) | 13 (30.2) | 33 (15.9) | 150 (23.9) | 44 (31.0) | 10 (27.0) | 54 (22.0) | 690 (20.9) | 0.014# |
| Calcium channel blockers | 402 (8.2) | 23 (8.5) | 6 (14.0) | 11 (5.3) | 38 (6.0) | 19 (13.4) | 11 (29.7) | 22 (8.9) | 272 (8.2) | <0.001# |
| Alpha blockers | 71 (1.5) | 8 (3.0) | 1 (2.3) | 0 (0) | 9 (1.4) | 6 (4.2) | 0 (0) | 6 (2.4) | 41 (1.2) | 0.010# |
| Psychoactive medications, | ||||||||||
| Overall | 444 (9.1) | 46 (16.9) | 6 (14.0) | 16 (7.7) | 67 (10.6) | 21 (14.5) | 3 (7.9) | 28 (11.3) | 257 (7.8) | <0.001# |
| Z-drugs | 109 (2.2) | 12 (4.4) | 2 (4.7) | 3 (1.4) | 14 (2.2) | 11 (7.8) | 1 (2.7) | 5 (2.0) | 61 (1.9) | <0.001# |
| Benzodiazepines | 140 (2.9) | 17 (6.3) | 0 (0.0) | 9 (4.3) | 15 (2.4) | 5 (3.5) | 2 (5.4) | 10 (4.1) | 82 (2.5) | 0.009# |
| Antidepressants | 281 (5.7) | 35 (12.9) | 4 (9.3) | 9 (4.3) | 47 (7.4) | 12 (8.3) | 1 (2.6) | 15 (6.1) | 158 (4.8) | <0.001# |
| OI during AS, | 1880 (38.4) | 130 (47.8) | 21 (48.8) | 93 (44.5) | 271 (42.9) | 57 (39.3) | 13 (34.2) | 103 (41.7) | 1,192 (36.0) | <0.001# |
| At least 1 fall in the past 12 months, | 960 (19.6) | 77 (28.3) | 6 (14.0) | 36 (17.3) | 125 (19.8) | 32 (22.1) | 7 (18.4) | 47 (19.0) | 630 (19.0) | 0.025# |
| At least 1 syncope in the past 12 months, | 226 (4.62) | 13 (4.8) | 1 (2.3) | 11 (5.3) | 23 (3.7) | 11 (7.8) | 2 (5.3) | 9 (3.6) | 156 (4.7) | 0.585# |
| Mean baseline SBP, mmHg (SD) | 135.8 (22.3) | 147.7 (24.9) | 142.1 (27.9) | 142.9 (25.0) | 140.3 (23.0) | 143.5 (23.0) | 141.8 (19.1) | 143.8 (24.3) | 132.4 (20.6) | <0.001* |
| Mean baseline heart rate (HR), beats per minute (SD) | 65.0 (9.9) | 61.9 (9.9) | 63.5 (9.8) | 61.2 (9.2) | 63.1 (9.5) | 67.1 (11.7) | 69.9 (10.9) | 65.0 (9.9) | 65.7 (9.7) | <0.001* |
*Kruskal–Wallis test, #Chi-square test.
Results of the fully adjusted logistic regression models (Models C)
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | Group 7 | Group 8 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| ||
| OI |
|
| 1.85 (0.98, 3.47) | 0.056 |
|
|
|
| 1.20 (0.84, 1.73) | 0.314 | 0.99 (0.49, 20.3) | 0.981 |
|
| (Base) |
| Falls |
|
| 0.64 (0.27, 1.56) | 0.326 | 0.86 (0.58, 1.26) | 0.440 | 1.00 (0.80, 1.26) | 0.957 | 0.90 (0.58, 1.40) | 0.641 | 0.91 (0.39, 2.12) | 0.824 | 0.94 (0.67, 1.33) | 0.732 | (Base) |
| Recent syncope | 0.91 (0.49, 1.66) | 0.750 | 0.56 (0.05, 4,21) | 0.658 | 1.27 (0.67, 2.41) | 0.464 | 0.72 (0.45, 1.16) | 0.180 | 1.29 (0.64, 2.58) | 0.478 | 0.60 (0.80, 4.47) | 0.616 | 0.74 (0.37, 1.50) | 0.409 | (Base) |
Statistically significant results are highlighted in bold.